ITGB1BP2 Biologics Sequence Review Report 2026: Integrin beta-1-binding protein 2 Similarity and Patent-Risk Signals

This IGFL1 Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It combines patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report.

Review date: 17 September 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A hit does not establish infringement. “Claimed” is a database annotation that still requires family consolidation, live-claim review and jurisdiction-specific claim construction.

Executive sequence-risk thesis

IGFL1 is a protein directed to Insulin growth factor-like family member 1. A reviewed UniProtKB/Swiss-Prot human record supplied the 110-aa full-length query. PatSnap’s all-patent protein search returned a closest hit at 100.00% query identity across 110/110; the record was marked Yes.

The screening conclusion is elevated diligence priority, not “blocked” or “clear.” Similarity must be interpreted by functional domain, construct architecture, target evidence and live-claim language. Common domains can drive high percentages without proving an asset-level collision, while a few substitutions at an active site, epitope or junction may matter disproportionately.

Sequence scope and MCP workflow

The full-length query was submitted with ls_sequence_search_submit against ALLPATENT and CLAIMS protein records, allowing gaps and using an E-value threshold and 20-record cap. Results were retrieved with ls_sequence_search_get_results; the closest hit was resolved through ls_sequence_fetch and compared with ls_sequence_alignment. ls_patent_sequence_fetch and ls_antibody_antigen_search supplied patent-sequence and target context.

Similarity search readout

The search returned 20 records. These are not unique inventions, enforceable claims or independent families. Publications can repeat the same sequence across jurisdictions, examples, comparators and continuations. Deduplicate by earliest priority, applicant, simple family and legal status before making business conclusions.

Module-level reading of the construct

The available query set contains one independently searchable protein module. Reviewers should separate catalytic, binding, transmembrane, signal-peptide and regulatory regions where applicable. A full-length match may be driven by conserved architecture outside the commercially decisive region.

Result volume is also a specificity check. A query that reaches the task cap is less discriminating than a smaller, concentrated set. Prioritize rare domains, active sites and junctions, then use broadly conserved regions as corroboration. This reduces the risk of treating evolutionary similarity as evidence of an asset-level collision.

Pairwise alignment: what the closest hit means

The selected comparison reported 110/110 identical positions, query coverage 110/110, E-value 8.04611e-79 and no gaps. The subject was sequence 492308, 110 aa, annotated “Protein PRO1274 precursor”. The direct step returned one pairwise alignment record.

Percentage identity alone is not a claim chart. Map mismatches to functional domains, binding interfaces, active sites, signal peptides, membrane segments, linker boundaries and claimed SEQ IDs. Search fragments and fusion constructs separately because a full-construct query can obscure conserved modules.

Antibody–antigen and patent-sequence evidence

The antibody–antigen search returned 2 records for IGFL1 in the Insulin growth factor-like family member 1 context. The leading patent record was CN120309727A, “Single-domain antibody targeting human IGFL1 and application thereof”.

CN120309727A returned 18 associated sequences. This provides traceability, but the list can include examples, controls, fragments and repeated disclosures.

Evidence strength and blind spots

The evidence is strongest for the exact query, alignment coordinates and records directly resolved by the MCP tools. It is weaker where aliases are absent, publications disclose fragments, or the result cap excludes lower-ranked families. Read the underlying sequence and target annotation before attributing a record to IGFL1.

Patent listings can contain screening libraries, consensus sequences, controls, antigens, primers and manufacturing elements. Conversely, claims may define a molecule through identity thresholds, functional language or genus formulas without reproducing the exact sequence. Combining similarity with target evidence improves prioritization but still does not create a legal conclusion.

Patent-risk interpretation

Diligence actions

1. Confirm the query matches the intended clinical or commercial construct.
2. Repeat searches for domains, functional motifs, junctions and nucleotide sequences, then cluster by patent family.
3. Annotate high-identity hits by active site, epitope, membrane segment and linker position.
4. Verify the returned sequence number and “claimed” annotation against the filed document.
5. Build jurisdiction-specific claim charts and document licenses or platform rights affecting Insulin growth factor-like family member 1 programs.
6. Rerun the workflow at the decision date because sequence and legal-status coverage changes.

Bottom line

IGFL1 has a traceable protein sequence. The combination of 100.00% closest-hit identity, Yes claim annotation, and 2 filtered antibody–antigen records and 18 directly fetched patent sequences supports elevated diligence priority. The defensible outcome is a domain-aware family and claim review—not a binary clearance statement.

Explore PatSnap Open Platform MCP Servers to produce sequence similarity and patent-risk reports for antibodies, proteins, peptides and nucleic-acid assets.

Sources and methodology notes

Query sequence: UniProtKB/Swiss-Prot reviewed human protein record. Evidence was retrieved through PatSnap Biology Modality MCP on 17 September 2026. Database annotations and legal status can change; rerun at the decision date.